https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35993 Thu 23 Jan 2020 14:49:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20771 vs as-needed 1·05, 0·92–1·20). We recorded no difference between treatment groups for time to recovery (adjusted p=0·79). Adherence to regular tablets (median tablets consumed per participant per day of maximum 6; 4·0 [IQR 1·6–5·7] in the regular group, 3·9 [1·5–5·6] in the as-needed group, and 4·0 [1·5–5·7] in the placebo group), and number of participants reporting adverse events (99 [18·5%] in the regular group, 99 [18·7%] in the as-needed group, and 98 [18·5%] in the placebo group) were similar between groups. Interpretation: Our findings suggest that regular or as-needed dosing with paracetamol does not affect recovery time compared with placebo in low-back pain, and question the universal endorsement of paracetamol in this patient group.]]> Sat 24 Mar 2018 08:00:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34278 Mon 25 Feb 2019 14:55:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51769 Mon 18 Sep 2023 14:29:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52679 Fri 20 Oct 2023 09:30:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49423 100) was determined from simulations for four previously proposed treatment regimens: (i) 400 mg once daily, (ii) an 800 mg loading dose followed by 400 mg once daily, (iii) 400 mg twice daily, and (iv) a 12 mg/kg loading dose followed by 6 mg/kg once daily. The effect of body weight (40, 70, 120 kg) and renal function (continuous renal replacement therapy (CRRT); 20, 60, 120, 180 mL/min creatinine clearance) on PTA was assessed. Results: Early (0–48 h) fluconazole target attainment for infections with a minimum inhibitory concentration (MIC) of 2 mg/L was highly variable. PTA was highest with an 800 mg loading dose for underweight (40 kg) patients and with a 12 mg/kg loading dose for the remainder. End-of-treatment PTA was highest with the 400 mg twice daily maintenance dosing for patients who were under- or normal weight and 6 mg/kg maintenance dosing for overweight (120 kg) patients. None of the fluconazole regimens reliably attained early targets for MICs of ≥4 mg/L. Conclusion: Current fluconazole dosing regimens do not achieve adequate early target attainment in critically ill adults, particularly in those who are overweight, have higher creatinine clearance, or are undergoing CRRT. Current fluconazole dosing strategies are generally inadequate to treat organisms with an MIC of ≥4 mg/L.]]> Fri 12 May 2023 15:09:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37035 Fri 07 Aug 2020 12:00:14 AEST ]]>